Andrei R. Shustov
Seattle Cancer Care Alliance(US)Cellectar Biosciences (United States)(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, T-cell and Retrovirus Studies, Cutaneous lymphoproliferative disorders research, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma(2015)1,102 cited
- → Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study(2012)983 cited
- → Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial(2018)710 cited
- → Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy(2012)667 cited
- → Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study(2011)637 cited
- → Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial(2018)630 cited